Following the great news yesterday about our agreement with apceth I am pleased to forward (below) a research note published today by leading analyst Darren Vincent from Shaw and Partners. It is encouraging that the research clearly identifies the significance of the apceth deal.
Yours sincerely
Ross Macdonald
Dr Ross A Macdonald
Managing Director and Chief Executive Officer
Cynata Therapeutics Limited
Flash Note
Cynata (CYP)
Commercial Interest Highlights Potential (Rec: Not covered)
EVENT
Following an initial technical evaluation of its Cymerus technology, CYP has announced that it has entered into a licensing option for an undisclosed upfront payment with apceth GmbH & Co for the exclusive use of Cymerus in the treatment of cancer.
HIGHLIGHTS
·Commercial acceptance of CYP’s technology is building. The licensing option of Cymerus with apceth, worth up to a potential $40m excluding royalties, follows the strategic alliance CYP announced last month with Regience K.K. These two deals indicate that: 1) Significant industry participants see the need for a scalable mesenchymal stem cell (MSC60 Castlereagh Street Sydney NSW 2000 Australia
T: +61 2 9238 1269 | M: 448712121 | [email protected]www.shawandpartners.com.au
CYP Price at posting:
37.5¢ Sentiment: Buy Disclosure: Held
